keyword
MENU ▼
Read by QxMD icon Read
search

Repurposing drugs

keyword
https://www.readbyqxmd.com/read/29922160/decost-a-new-approach-in-drug-repurposing-from-control-system-theory
#1
Thanh M Nguyen, Syed A Muhammad, Sara Ibrahim, Lin Ma, Jinlei Guo, Baogang Bai, Bixin Zeng
In this paper, we propose DeCoST (Drug Repurposing from Control System Theory) framework to apply control system paradigm for drug repurposing purpose. Drug repurposing has become one of the most active areas in pharmacology since the last decade. Compared to traditional drug development, drug repurposing may provide more systematic and significantly less expensive approaches in discovering new treatments for complex diseases. Although drug repurposing techniques rapidly evolve from "one: disease-gene-drug" to "multi: gene, dru" and from "lazy guilt-by-association" to "systematic model-based pattern matching," mathematical system and control paradigm has not been widely applied to model the system biology connectivity among drugs, genes, and diseases...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29921838/patient-derived-organoids-to-model-rare-prostate-cancer-phenotypes
#2
Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta, Verena Sailer, Aram Vosoughi, Chantal Pauli, Yelena Churakova, Cynthia Cheung, Lesa Dayal Deonarine, Terra J McNary, Rachele Rosati, Scott T Tagawa, David M Nanus, Juan Miguel Mosquera, Charles L Sawyers, Yu Chen, Giorgio Inghirami, Rema A Rao, Carla Grandori, Olivier Elemento, Andrea Sboner, Francesca Demichelis, Mark A Rubin, Himisha Beltran
A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients...
June 19, 2018: Nature Communications
https://www.readbyqxmd.com/read/29920284/an-in-vitro-test-system-for-compounds-that-modulate-human-inflammatory-macrophage-polarization
#3
Hiromi Shiratori, Carmen Feinweber, Sonja Luckhardt, Nadja Wallner, Gerd Geisslinger, Andreas Weigert, Michael J Parnham
Macrophages undergo activation by pathophysiological stimuli to pro-inflammatory and bactericidal, or wound-healing and anti-inflammatory phenotypes, termed M1 or M2, respectively. Dysregulation of the M1-M2 balance is often associated with inflammatory diseases. Therefore, mechanisms of macrophage polarization may reveal new drug targets. We profiled six compounds with claimed modulatory effects on macrophage polarization using peripheral blood monocyte-derived macrophages. Based on the distinct mRNA or protein expression in macrophages stimulated either with M1 [lipopolysaccharide (LPS) + interferon-γ, IFNγ] or M2 interleukin-4 (IL-4) stimuli, we selected a combination of M1 (IL1β, tumor necrosis factor-α,TNFα, CC chemokine receptor 7, CCR7 and CD80) and M2 (chemokine (C-C motif) ligand 22, CCL22, CD200R and mannose receptor C type 1, MRC1) markers to monitor drug effects on "M1 polarization" or cells "pre-polarized to M1"...
June 16, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29917287/new-drugs-and-regimens-for-tuberculosis
#4
REVIEW
Kwok-Chiu Chang, Eric Nuermberger, Giovanni Sotgiu, Chi-Chiu Leung
Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public health threats worldwide. Although the last decade has witnessed advances in rapid diagnostic tools and use of repurposed and novel drugs for better managing drug-resistant TB, we need an appropriate TB control strategy and a well-functioning health infrastructure to ensure optimal operational use of rapid tests, judicious use of effective treatment regimens that can be rapidly tailored according to the drug resistance profile and timely management of risk factors and co-morbidities that promote infection and its progression to disease...
June 19, 2018: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/29911689/rapid-recovery-of-clofazimine-loaded-nanoparticles-with-long-term-storage-stability-as-anti-cryptosporidium-therapy
#5
Jie Feng, Yingyue Zhang, Simon A McManus, Kurt D Ristroph, Hoang D Lu, Kai Gong, Claire E White, Robert K Prud'homme
While the formulation of nanoparticle (NP) suspensions has been widely applied in materials and life science, the recovery of NPs from such a suspension into a solid state is practically important to confer long-term storage stability. However, solidification, while preserving the original nanoscale properties, remains a formidable challenge in the pharmaceutical and biomedical applications of NPs. Herein we combined flash nanoprecipitation (FNP) and spray-drying as a nanofabrication platform for NP formulation and recovery without compromising the dissolution kinetics of the active ingredient...
May 25, 2018: ACS applied nano materials
https://www.readbyqxmd.com/read/29908958/antifungal-drug-ciclopirox-olamine-reduces-hsv-1-replication-and-disease-in-mice
#6
Kaelin M Bernier, Lynda A Morrison
Herpes simplex virus (HSV)-1 and HSV-2 cause painful blisters and shallow ulcers in exposed skin and mucosae during primary or recurrent infection. In addition, recurrent and potentially blinding HSV-1 infections of the eye afflict nearly half a million persons in the U.S. Current clinical therapies rely on nucleoside analog drugs such as acyclovir (ACV) or ganciclovir to ameliorate primary infections and reduce the frequency and duration of reactivations. However, these treatments do not fully suppress viral shedding and drug-resistant mutants develop in the eye and in vulnerable, immunosuppressed patients...
June 14, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29907742/nmda-antagonists-for-treating-the-non-motor-symptoms-in-parkinson-s-disease
#7
REVIEW
Brigitte Vanle, William Olcott, Jaime Jimenez, Luma Bashmi, Itai Danovitch, Waguih William IsHak
Among patients with Parkinson's disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life. There is a critical need for alternative pharmacological methods to treat PD depression, as mainstream antidepressant drugs are largely ineffective in this population. Currently, there are no recommendations for the optimal treatment of PD neuropsychiatric symptoms. Given the dual antidepressant and anti-dyskinetic effects of ketamine and other N-methyl-D-aspartate (NMDA) antagonists for PD, this review aims to examine the current evidence of NMDA antagonists for treating neuropsychiatric symptoms, including memantine, amantadine, ketamine, dizoclopine, and d-cycloserine...
June 15, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29907425/repurposing-steroidogenesis-inhibitors-for-the-therapy-of-neuropsychiatric-disorders-promises-and-caveats
#8
REVIEW
Roberto Frau, Marco Bortolato
Steroids exert a profound influence on behavioral reactivity, by modulating the functions of most neurotransmitters and shaping the impact of stress and sex-related variables on neural processes. This background - as well as the observation that most neuroactive steroids (including sex hormones, glucocorticoids and neurosteroids) are synthetized and metabolized by overlapping enzymatic machineries - points to steroidogenic pathways as a powerful source of targets for neuropsychiatric disorders. Inhibitors of steroidogenic enzymes have been developed and approved for a broad range of genitourinary and endocrine dysfunctions, opening to new opportunities to repurpose these drugs for the treatment of mental problems...
May 11, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29907424/repurposing-drugs-to-treat-l-dopa-induced-dyskinesia-in-parkinson-s-disease
#9
REVIEW
Tom H Johnston, Alix M B Lacoste, Naomi P Visanji, Anthony E Lang, Susan H Fox, Jonathan M Brotchie
In this review, we discuss the opportunity for repurposing drugs for use in l-DOPA-induced dyskinesia (LID) in Parkinson's disease. LID is a particularly suitable indication for drug repurposing given its pharmacological diversity, translatability of animal-models, availability of Phase II proof-of-concept (PoC) methodologies and the indication-specific regulatory environment. A compound fit for repurposing is defined as one with appropriate human safety-data as well as animal safety, toxicology and pharmacokinetic data as found in an Investigational New Drug (IND) package for another indication...
June 1, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29906585/medical-concept-normalization-in-social-media-posts-with-recurrent-neural-networks
#10
Elena Tutubalina, Zulfat Miftahutdinov, Sergey Nikolenko, Valentin Malykh
Text mining of scientific libraries and social media has already proven itself as a reliable tool for drug repurposing and hypothesis generation. The task of mapping a disease mention to a concept in a controlled vocabulary, typically to the standard thesaurus in the Unified Medical Language System (UMLS), is known as medical concept normalization. This task is challenging due to the differences in the use of medical terminology between health care professionals and social media texts coming from the lay public...
June 12, 2018: Journal of Biomedical Informatics
https://www.readbyqxmd.com/read/29906562/amino-acid-conjugated-chitosan-nanoparticles-for-the-brain-targeting-of-a-model-dipeptidyl-peptidase-4-inhibitor
#11
Jessica Fernandes, M Vivek Ghate, Sanchari Basu Mallik, Shaila A Lewis
Saxagliptin (SAX) is dipeptidyl peptidase-4 enzyme inhibitor molecule now explored for its activity in the therapy of Alzheimer's disease. Being extremely hydrophilic, it is unable to permeate the blood-brain barrier by the conventional therapy modalities. Further repurposing the drug, SAX is associated with a reduction in the blood sugar level in the periphery. In the present study, the chitosan-L-valine conjugate was synthesized by carbodiimide chemistry. The conjugate was then used to prepare nanoparticles encapsulating SAX...
June 12, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29906501/repurposing-drugs-as-inhaled-therapies-in-asthma
#12
Sandra D Anderson
For the first 40 years of the 20th century treatment for asthma occurred in response to an asthma attack. The treatments were given by injection or orally and included the adrenergic agonists adrenalin/epinephrine and ephedrine and a phosphodiesterase inhibitor theophylline. Epinephrine became available as an aerosol in 1930. After 1945, isoprenaline, a non-selective beta agonist, became available for oral use but it was most widely used by inhalation. Isoprenaline was short-acting with unwanted cardiac effects...
June 12, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29901742/transcriptomic-rnaseq-drug-screen-in-cerebrocortical-cultures-towards-novel-neurogenetic-disease-therapies
#13
Jeremiah Hadwen, Sarah Schock, Alan Mears, Robert Yang, Philippe Charron, Liying Zhang, Hualin S Xi, Alex MacKenzie
Rare monogenic diseases affect millions worldwide; although over 4,500 rare disease genotypes are known, disease-modifying drugs are available for only 5% of them. The sheer number of these conditions combined with their rarity precludes traditional costly drug discovery programs. An economically viable alternative is to repurpose established drugs for rare diseases. Many genetic diseases result from increased or decreased protein activity and identification of clinically approved drugs which moderate this pathogenic dosage holds therapeutic potential...
June 13, 2018: Human Molecular Genetics
https://www.readbyqxmd.com/read/29901247/joint-contracture-is-reduced-by-intra-articular-implantation-of-rosiglitazone-loaded-hydrogels-in-a-rabbit-model-of-arthrofibrosis
#14
Diren Arsoy, Christopher G Salib, William H Trousdale, Meagan E Tibbo, Afton K Limberg, Anthony Viste, Eric A Lewallen, Nicolas Reina, Michael J Yaszemski, Daniel J Berry, Andre J van Wijnen, Mark E Morrey, Joaquin Sanchez-Sotelo, Matthew P Abdel
Trauma, surgery, and other inflammatory conditions can lead to debilitating joint contractures. Adjunct pharmacologic modalities may permit clinical prevention and treatment of recalcitrant joint contractures. We investigated the therapeutic potential of rosiglitazone by intra-articular delivery via oligo[poly(ethylene glycol)fumarate] (OPF) hydrogels in an established rabbit model of arthrofibrosis. OPF hydrogels loaded with rosiglitazone were characterized for drug elution properties upon soaking in minimum essential media (MEM) with 10% fetal bovine serum and measurements of drug concentrations via High Performance Liquid Chromatography (HPLC)...
June 14, 2018: Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society
https://www.readbyqxmd.com/read/29899092/screening-and-identification-of-lassa-virus-entry-inhibitors-from-an-fda-approved-drugs-library
#15
Peilin Wang, Yang Liu, Guangshun Zhang, Shaobo Wang, Jiao Guo, Junyuan Cao, Xiaoying Jia, Leike Zhang, Gengfu Xiao, Wei Wang
Lassa virus (LASV) belongs to the Mammarenavirus genus (family Arenaviridae ) and causes severe hemorrhagic fever in humans. At present, there are no Food and Drug Administration (FDA)-approved drugs or vaccines specific for LASV. Herein, high-throughput screening of an FDA-approved drug library was performed against LASV entry by using pseudotype virus bearing LASV envelope glycoprotein (GPC). Two hit compounds, lacidipine and phenothrin, were identified as LASV entry inhibitors in the micromolar range. A mechanistic study revealed that both compounds inhibited LASV entry by blocking low-pH-induced membrane fusion...
June 13, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29895906/repositioning-of-omarigliptin-as-a-once-weekly-intranasal-anti-parkinsonian-agent
#16
Bassam M Ayoub, Shereen Mowaka, Marwa M Safar, Nermeen Ashoush, Mona G Arafa, Haidy E Michel, Mariam M Tadros, Mohamed M Elmazar, Shaker A Mousa
Drug repositioning is a revolution breakthrough of drug discovery that presents outstanding privilege with already safer agents by scanning the existing candidates as therapeutic switching or repurposing for marketed drugs. Sitagliptin, vildagliptin, saxagliptin & linagliptin showed antioxidant and neurorestorative effects in previous studies linked to DPP-4 inhibition. Literature showed that gliptins did not cross the blood brain barrier (BBB) while omarigliptin was the first gliptin that crossed it successfully in the present work...
June 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29893860/is-it-time-for-a-paradigm-shift-in-drug-research-and-development-in-endometriosis-adenomyosis
#17
Sun-Wei Guo, Patrick G Groothuis
BACKGROUND: The drug research and development (R&D) for endometriosis/adenomyosis has been painfully slow. Most completed clinical trials on endometriosis did not publish their results, and presumably failed. While few published trials did report how they foundered, the reasons why they failed are often completely unclear. Surprisingly, there has been no open discussion on why these trials failed. If the causes for these failed trials remain unelucidated, mistakes made in these failed trials may be repeated in the future...
June 11, 2018: Human Reproduction Update
https://www.readbyqxmd.com/read/29891981/cancer-drug-response-profile-scan-cdrscan-a-deep-learning-model-that-predicts-drug-effectiveness-from-cancer-genomic-signature
#18
Yoosup Chang, Hyejin Park, Hyun-Jin Yang, Seungju Lee, Kwee-Yum Lee, Tae Soon Kim, Jongsun Jung, Jae-Min Shin
In the era of precision medicine, cancer therapy can be tailored to an individual patient based on the genomic profile of a tumour. Despite the ever-increasing abundance of cancer genomic data, linking mutation profiles to drug efficacy remains a challenge. Herein, we report Cancer Drug Response profile scan (CDRscan) a novel deep learning model that predicts anticancer drug responsiveness based on a large-scale drug screening assay data encompassing genomic profiles of 787 human cancer cell lines and structural profiles of 244 drugs...
June 11, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29891506/licofelone-enhances-the-efficacy-of-paclitaxel-in-ovarian-cancer-by-reversing-drug-resistance-and-tumor-stem-like-properties
#19
Jeff Hirst, Harsh B Pathak, Stephen Hyter, Ziyan Y Pessetto, Thuc Ly, Stefan Graw, Devin C Koestler, Adam J Krieg, Katherine F Roby, Andrew K Godwin
Drug development for front-line treatment of epithelial ovarian cancer (EOC) has been stagnant for almost three decades. Traditional cell culture methods for primary drug screening do not always accurately reflect clinical disease. To overcome this barrier, we grew a panel of EOC cell lines in three-dimensional (3D) cell cultures to form multicellular tumor spheroids (MCTS). We characterized these MCTS for molecular and cellular features of EOC and performed a comparative screen with cells grown using two-dimensional (2D) cell culture to identify previously unappreciated anti-cancer drugs...
June 11, 2018: Cancer Research
https://www.readbyqxmd.com/read/29890243/repurposing-of-statins-via-inhalation-to-treat-lung-inflammatory-conditions
#20
Peta Bradbury, Daniela Traini, Alaina J Ammit, Paul M Young, Hui Xin Ong
Despite many therapeutic advancements over the past decade, the continued rise in chronic inflammatory lung diseases incidence has driven the need to identify and develop new therapeutic strategies, with superior efficacy to treat these diseases. Statins are one class of drug that could potentially be repurposed as an alternative treatment for chronic lung diseases. They are currently used to treat hypercholesterolemia by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, that catalyses the rate limiting step in the mevalonate biosynthesis pathway, a key intermediate in cholesterol metabolism...
June 8, 2018: Advanced Drug Delivery Reviews
keyword
keyword
90634
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"